Global Ornithine Transcarbamylase Deficiency (OTC Deficiency) Market Anticipated to Expand Rapidly From 2025 to 2029
Use Code ONLINE20 to Save 20% On Global Market Reports – Gain Access to Trusted Market Data, Growth Indicators, and Industry Analytics
What Are the Key Growth Indicators and Market Expansion Estimates for the Ornithine Transcarbamylase Deficiency (OTC Deficiency) Market Through 2029?
The ornithine transcarbamylase deficiency (otc deficiency) market size has grown strongly in recent years. It will grow from $0.83 billion in 2024 to $0.89 billion in 2025 at a compound annual growth rate (CAGR) of 6.9%. The growth in the historic period can be attributed to increased awareness of rare metabolic disorders, improvement in genetic screening and diagnostics, improved neonatal screening programs, rising prevalence of genetic testing in rare diseases, and improved neonatal screening programs.
The ornithine transcarbamylase deficiency (otc deficiency) market size is expected to see strong growth in the next few years. It will grow to " $1.15 billion in 2029 at a compound annual growth rate (CAGR) of 6.8%. The growth in the forecast period can be attributed to increasing awareness and diagnosis, rising prevalence of urea cycle disorders, growing focus on rare disease treatment, rising research and clinical trials, and improved patient access to treatments. Major trends in the forecast period include advancements in genetic therapies and gene editing technologies, development of enzyme replacement therapies, collaborative research initiatives and partnerships, technological advancements in diagnostic tools, government funding and incentives for orphan drugs.
Get your free report sample today:
Which Key Drivers Are Fueling Growth in the Ornithine Transcarbamylase Deficiency (OTC Deficiency) Market?
The growing demand for gene therapies is expected to propel the growth of the ornithine transcarbamylase deficiency market going forward. Gene therapy refers to a medical treatment or technique that involves altering or manipulating a person's genetic material to treat or prevent diseases. The demand for gene therapies is attributed to the rising prevalence of genetic disorders, as these conditions often have limited treatment options, and gene therapy offers a promising approach to addressing the root cause rather than just managing symptoms. Ornithine transcarbamylase deficiency demonstrates the promise of gene therapies by correcting the genetic mutation that disrupts the urea cycle, allowing for targeted treatment to restore metabolic function and prevent toxic ammonia accumulation. For instance, in January 2024, according to the American Society of Gene & Cell Therapy, a US-based organization for gene and cell therapy, in Q4 2023, the number of gene therapies in Phase III increased by 10% from the previous quarter, marking the first rise since Q3 2022. Therefore, the growing demand for gene therapies is driving the growth of the ornithine transcarbamylase deficiency market.
How Is the Ornithine Transcarbamylase Deficiency (OTC Deficiency) Market Categorized Based on Key Segments?
The ornithine transcarbamylase deficiency (otc deficiency)market covered in this report is segmented –
1) By Product Type: DTX-301; SEL-313; SHP-641; PRX-OTC
2) By Treatment Type: Gene Therapy; Liver Transplant; Dietary Management; Other Treatement Type
3) By Diagnosis: Genetic Testing; Ammonia Level Testing
4) By End-User: Hospitals; Specialty Clinics; Research Institutes; Other End Users
Subsegments:
1) By DTX-301: Adeno-Associated Virus (AAV)-Based Gene Therapy; Intravenous Dosing Formulation
2) By SEL-313: Immune Tolerance-Inducing Therapy; Enzyme Replacement Therapy (ERT) Combination
3) By SHP-641: Small Molecule Therapy; mRNA-Based Therapeutic Approach
4) By PRX-OTC: Recombinant Enzyme Replacement Therapy; Protein Engineering-Based Therapy
What Are the Key Industry Trends Driving Growth in the Ornithine Transcarbamylase Deficiency (OTC Deficiency) Market?
Major companies operating in the ornithine transcarbamylase deficiency (OTC Deficiency) market are focusing on developing innovative therapies such as mRNA therapeutics to enhance treatment efficacy and address the underlying genetic cause of OTC deficiency. mRNA therapeutics are a class of treatments that use messenger RNA (mRNA) to instruct cells to produce specific proteins for therapeutic purposes. These therapies leverage the body's natural protein synthesis machinery to treat diseases, including genetic disorders, infectious diseases, and cancers. For instance, in June 2023, Arcturus Therapeutics Holdings Inc., a US-based biotechnology company, received Fast Track Designation from the U.S. Food and Drug Administration (FDA) for ARCT-810, its mRNA therapeutic candidate for ornithine transcarbamylase (OTC) deficiency. This designation is intended to accelerate the drug's development and review process, offering potential benefits such as more frequent FDA interactions and priority review. ARCT-810 is designed to enable patients with OTC deficiency, a urea cycle disorder, to produce functional OTC enzyme in their liver cells, addressing the underlying cause of the condition and potentially improving their quality of life.
Who Are the Leading Market Participants in the Ornithine Transcarbamylase Deficiency (OTC Deficiency) Market?
Major companies operating in the ornithine transcarbamylase deficiency (OTC deficiency) market are Thermo Fisher Scientific, Novartis AG, GlaxoSmithKline plc, Roche Holding AG, Eli Lilly and Company, Amgen Inc., Merck & Co. Inc, Biogen Idec, Bausch Health Companies Inc, Alexion Pharmaceuticals, Sobi, BioMarin Pharmaceutical Inc, Glenmark Pharmaceuticals Ltd., Nutricia, Vertex Pharmaceuticals Incorporated, Ultragenyx Pharmaceutical Inc, Arcturus Therapeutics, Regenxbio, OrphanPacific Inc, Ucyclyd Pharma Inc.
Get the detailed ornithine transcarbamylase deficiency (otc deficiency) market report today
Which Regions Are Driving the Highest Demand in the Ornithine Transcarbamylase Deficiency (OTC Deficiency) Market?
North America was the largest region in the ornithine transcarbamylase deficiency (OTC Deficiency) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the ornithine transcarbamylase deficiency (OTC deficiency) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Contact Us:
The Business Research Company: https://thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Comments
Post a Comment